1
|
Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34:281-8. [PMID: 16500114 DOI: 10.1016/j.biologicals.2005.11.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2005] [Revised: 08/08/2005] [Accepted: 11/22/2005] [Indexed: 10/25/2022] Open
Abstract
This study summarises the biochemical and functional properties of a new generation plasma-derived, double virus inactivated von Willebrand Factor/Factor VIII (VWF/FVIII) concentrate, Wilate, targeted for the treatment of both von Willebrand disease (VWD) and haemophilia A. The manufacturing process comprises two chromatographic steps based on different performance principles, ensuring a high purity of the concentrate (mean specific activity in 15 consecutive production batches: 122 IU FVIII:C/mg total protein) and, thus, minimising the administered protein load to the patient (specification: < or = 15 mg total protein per 900 IU Wilate). The optimised solvent/detergent (S/D) treatment and prolonged terminal dry-heat (PermaHeat) treatment of the lyophilised product at a specified residual moisture (RM) provide two mechanistically independent, effective and robust virus inactivation procedures for enveloped viruses and one step for non-enveloped viruses. These process steps are aggressive enough to inactivate viruses efficiently, but yet gentle enough to maintain the structural integrity and function of the VWF and FVIII molecules, as proven by state-of-the-art assays covering the diverse features of importance. The VWF multimeric pattern is close to the one displayed by normal plasma, with a consistent content of more than 10 multimers, but a relatively lower portion of the very high multimers. The multimeric triplet structure is normal, underlining the gentle and effective manufacturing process, which does not require the addition of protein stabilisers at any step. The balanced activity ratio of VWF to FVIII is close to that of plasma from healthy subjects, rendering Wilate suitable also for the safe and effective treatment of patients with VWD.
Collapse
Affiliation(s)
- M Stadler
- Octapharma Pharmazeutika Produktionsges.m.b.H., Research and Development, Oberlaaerstrasse 235, A-1100 Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Abstract
OCTAPLAS is a cell-free standardized blood group specific human coagulation active plasma for transfusion. The viral safety is mainly based on the treatment with solvent/detergent. SD is known to irreversibly inactivate the lipid enveloped viruses including HIV 1 + 2, HBV and HCV and has been recommended both by European guidelines and the FDA. The potential limitation of each inactivation method should be validated according to the current EU-guidelines CPMP/BWP/268/95 and CPMP/BWP/269/95. Our studies demonstrate that the SD method inactivates lipid enveloped viruses within a few minutes to below the limit of detection. The concentration of the SD reagents as well as several other process parameters chosen for the virus inactivation step of plasma pools of different protein and lipid composition result in a high safety margin towards the clinically relevant viruses.
Collapse
Affiliation(s)
- L Biesert
- Octapharma AG, Ziegelbrücke, Switzerland.
| | | |
Collapse
|
3
|
Biesert L, Poplavsky JL, Suhartono H, Strançar A, Josic D, Schwinn H, Schütz R. P4-14 Sécurité virale d'octaplas: études de validation virale. Transfus Clin Biol 1998. [DOI: 10.1016/s1246-7820(98)80076-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Suhartono H, Biesert L. Das Solvent/Detergent-Verfahren - eine robuste, aber sehr schonende Virusinaktivierungsmethode für Humanplasma. Hamostaseologie 1997. [DOI: 10.1055/s-0038-1659998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
ZusammenfassungOctaplas® ist ein zellfreies, standardisiertes, virusinaktiviertes Humanplasma. Die Virussicherheit basiert vorrangig auf der Behandlung mit einem definierten Gemisch aus Solvent und Detergens (SD). Dieses Verfahren zur Inaktivierung von Viren wird weltweit für nahezu alle Plasmapräparate von zahlreichen Herstellern eingesetzt und ist in den neuesten europäischen Richtlinien als sehr effiziente und sichere Methode empfohlen worden. SD inaktiviert irreversibel die lipid-umhüllten Viren einschließlich HIV 1 +2, HBV und HCV. Eine mögliche Limitierung jedes Virusinaktivierungsverfahrens ist nach den EU-Richtlinien CPMP/BWP/268/95 und CPMP/BWP/269/95 experimentell zu belegen. Gemäß diesen Anforderungen wurden folgende Parameter untersucht: Gesamtkapazität dieses Inaktivierungsverfahrens, minimal benötigte Prozeßdauer und SD-Konzentration zur Virusinaktivierung unter die Nachweisgrenze, Einfluß von Plasmaprotein-und Plasmalipidgehalt, Einfluß der Prozeßtemperatur und Nachweis der Homogenität der SD-Reagenzien im Produktionsprozeß. Unsere Validierungsstudien belegen die Robustheit der SD-Methode, lipidumhüllte Viren innerhalb weniger Minuten vollständig zu inaktivieren. Die bei der Produktion von Octaplas® eingesetzte Konzentration von SD (1 % TNBP und 1 % Triton X-100) und die speziellen Parameter der Prozeßführung wie Dauer, Temperatur und Rührbedingungen garantieren für die Plasmapools mit ihrer unterschiedlichen Protein- und Lipidzusam-mensetzung einen hohen Sicherheitsgewinn hinsichtlich der klinisch relevanten Viren.
Collapse
|
5
|
Abstract
The inactivation of both transfusion-relevant and model viruses by modified pasteurisation (10 hours at 63 degrees C in solution) has been evaluated following the established guidelines of the EU CPMP Ad Hoc Working Party on Biotechnology/Pharmacy. This heat treatment was introduced into the manufacturing process of OCTAVI, a very high purity factor VIII concentrate stabilized only by von Willebrand factor, in the presence of a proprietary mixture of low molecular weight stabilizers. Both enveloped (human immunodeficiency virus, Sindbis virus, herpes simplex virus, pseudorabies virus) and nonenveloped viruses (poliovirus, Coxsackievirus, hepatitis A virus) were inactivated by this heating step by more than 4.7 log10. The combination of the solvent/detergent step used in the manufacture of OCTAVI with this modified pasteurization leads to a double virus-inactivated factor VIII concentrate (OCTATE) with a viral safety distinctly superior to monoinactivated products.
Collapse
Affiliation(s)
- L Biesert
- Octapharma AG, Ziegelbrücke, Switzerland
| | | | | | | | | | | |
Collapse
|
6
|
Horvat S, Varga-Defterdarović L, Horvat J, Jukić R, Kantoci D, Chung NN, Schiller PW, Biesert L, Pfützner A, Suhartono H. Synthesis and bioactivity studies of 1-adamantanamine derivatives of peptides. J Pept Sci 1995; 1:303-10. [PMID: 9223009 DOI: 10.1002/psc.310010505] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Small enkephalin-related peptides containing a 1-adamantanamine moiety coupled through an amide linkage at the C-terminus were synthesized. Several of the compounds showed high mu opioid activity and mu receptor selectivity. The new adamantanamine derivatives were also examined for antiviral activity against HIV-1 in a cell culture system. Some of them inhibited syncytia formation even when the antigen assay gave evidence for viral replication.
Collapse
Affiliation(s)
- S Horvat
- Department of Organic Chemistry and Biochemistry, Ruder Bosković Institute, Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
The inactivation of both transfusion-relevant and model viruses by modified pasteurization has been evaluated following the established guidelines of the European Union Committee for Proprietary Medical Products Ad Hoc Working Party on Biotechnology/Pharmacy. This heat treatment in solution for 10 h at 63 degrees C was introduced into the manufacturing process of OCTAVI, a very high purity factor VIII concentrate stabilized by von Willebrand factor. It could be demonstrated that both enveloped (human immunodeficiency virus, herpes simplex virus, pseudorabies virus) and non-enveloped viruses (poliovirus, coxsackievirus, hepatitis A virus) were inactivated by this heating step with an efficacy of greater than 4.5 log10 TCID50. The combination of the solvent/detergent step already used in the manufacture with this modified pasteurization leads to a double virus-inactivated factor VIII concentrate (OCTAVI SDPlus) with a viral safety distinctly superior to monoinactivated products.
Collapse
Affiliation(s)
- L Biesert
- Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany
| | | | | | | | | |
Collapse
|
8
|
Görlitzer K, Wilpert C, Rübsamen-Waigmann H, Suhartono H, Wang L, Immelmann A. [Pyrido(3,2-e)(1,4)diazepines--synthesis and testing of anti-HIV-1 activity]. Arch Pharm (Weinheim) 1995; 328:247-55. [PMID: 7763140 DOI: 10.1002/ardp.19953280308] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Starting from the commercially available 6-methyl-2-pyridylamine (1) the pyrido[3,2-e][1,4]diazepine 14a was synthesized in 12 steps with 7% total yield. 14a, the N-methyl derivative 14b, the thiolactam 15a, the amidine 16, and the 1,2,4-triazole 17 were tested for anti-HIV-1-activity. None of the compounds tested possesses antiviral activity comparable to that of zidovudine (3'-azido-3'-desoxythymidine = AZT).
Collapse
Affiliation(s)
- K Görlitzer
- Institut für Pharmazeutische Chemie, Technischen Universität Braunschweig
| | | | | | | | | | | |
Collapse
|
9
|
Biesert L, Gärtner T, Lemon S, Horowitz B, Suhartono H, Wang L, Brede H. OCTAPLAS: Eine virusinaktivierte Alternative zu gefrorenem Frischplasma. Transfus Med Hemother 1995. [DOI: 10.1159/000223169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Seit ein paar Jahren wird in Deutschland und einigen europäischen Ländern ein nach dem Solvent/Detergent(SD)-Verfahren behandeltes Plasma (OCTAPLAS) klinisch eingesetzt. Die transfusionsrelevanten Viren HIV, HBV, HCV sowie CMV, die lipidumhüllt sind, werden während der Herstellung durch das SD-Verfahren schnell und vollständig inaktiviert. Obwohl Viren ohne Lipidhülle in ihrer Infektiosität hierdurch nicht beeinträchtigt werden, kommt es durch die nachfol-gende Entfernung der SD-Reagenzien zu einer deutlichen Virusverminderung. Zusätzlich tragen neutralisierende Antikörper im Plasmapool, z. B. gegenüber HAV, deutlich zur Virussicherheit des Endproduktes OCTAPLAS bei.
Collapse
|
10
|
Rübsamen-Waigmann H, Schröder B, Biesert L, Bauermeister CD, von Briesen H, Suhartono H, Zimmermann F, Brede HD, Regeniter A, Gerte S. Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen. Infection 1991; 19 Suppl 2:S77-82. [PMID: 1673119 DOI: 10.1007/bf01644472] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In order to find parameters which allow the assessment of the clinical state of HIV patients with or without antiviral therapy, viral cultures on lymphocytes and monocytes/macrophages, CD4-cell counts, HIV antigen, beta 2-microglobulin and serum cholesterol were evaluated for their predictive value. As had been shown previously for lymphocytes, the efficiency of viral isolation on macrophages also depends on the disease stage (CDC) of the patients and thus has a high predictive value. A multivariant discriminant analysis showed that the combination of beta 2-microglobulin, viral antigen, CD4+ cell count and HDL cholesterol predicted the outcome of viral cultures with 80% accuracy. While viral antigen, CD4+ cell counts and beta 2-microglobulin had been known, HDL cholesterol deserves further evaluation as prognostic parameter. The analysis of HIV derived from patients with AZT showed a 20-200-fold in vitro drug resistance after seven to 24 months of therapy. DNA sequence determination of such strains isolated from AZT patients over time showed only two of the amino acid exchanges described in the literature for resistant strains and an additional Val60-Ile transition after 32 months of therapy.
Collapse
Affiliation(s)
- H Rübsamen-Waigmann
- Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Biesert L, Adamski M, Zimmer G, Suhartono H, Fuchs J, Unkelbach U, Mehlhorn RJ, Hideg K, Milbradt R, Rübsamen-Waigmann H. Anti-human immunodeficiency virus (HIV) drug HOE/BAY946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis. Med Microbiol Immunol 1990; 179:307-21. [PMID: 1965549 DOI: 10.1007/bf00189609] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The polysulfated polyxylan HOE/BAY946, which has been tested in two pilot studies in ARC/AIDS patients and in asymptomatic HIV carries in Germany, was believed to act by inhibiting virus attachment to the cell. However, the drug was also found to reduce the amount of HIV particles released from infected peripheral blood mononuclear cells (PBMC) in vitro. Furthermore, preincubation of PBMC with the drug led to a partial inhibition of a following HIV infection, suggesting that the drug also affects virus entry. Electron Paramagnetic Resonance (EPR) measurements on uninfected human lymphocytes using 5-proxyl-nonane as spin label demonstrated smaller hyperfine coupling constant (aN) values in the presence of HOE/BAY946 or dextran sulfate 5000. Accordingly, h-1p/h-1H ratios were decreased, indicating increased plasma membrane hydrophobicity and a membrane-stabilizing effect of the drugs. Culture of the chronically HIV-infected monocytic cell line U937/HIV-2D194 in the presence of HOE/BAY946 specifically and drastically reduced the release of virions and the intracellular synthesis of viral proteins as determined by radioimmunoprecipitation and reverse transcriptase assays. In conclusion, although the EPR studies showed a physico-chemical effect on membrane polarity, HOE/BAY946 and dextran sulfate clearly affect processes beyond the cell membrane. Thus, in contrast to previous reports suggesting that polysulfated sugars affect HIV only by inhibiting virus binding to uninfected cells, they clearly inhibit HIV in infected cells as well and appear to have a pleiotropic mode of action. Such drugs may be less likely to result in viral resistance after prolonged application than substances acting only on one step in the life cycle of the virus.
Collapse
Affiliation(s)
- L Biesert
- Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt, Federal Republic of Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Biesert L, Suhartono H, Winkler I, Meichsner C, Helsberg M, Hewlett G, Klimetzek V, Mölling K, Schlumberger HD, Schrinner E. Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound. AIDS 1988; 2:449-57. [PMID: 2468349 DOI: 10.1097/00002030-198812000-00007] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Xylanpoly-(hydrogen sulphate) disodium salt with a molecular weight of about 6000 daltons (HOE/BAY 946) completely inhibited syncytium formation induced by the infection of T lymphocytes with HIV as well as viral replication at concentrations above 25 micrograms/ml. This dose was found to be inhibitory for several strains of HIV-1 and HIV-2. Low molecular weight fractions of the compound were less active against HIV, and high molecular derivatives were as active as HOE/BAY 946. A direct influence of the drug on the infectivity of the virus could not be demonstrated. The drug inhibited the reverse transcriptase of HIV. Treatment of permanently HIV-infected U937 cells resulted in a drastic reduction of virus particles released into the supernatant and points to an additional mode of action. A therapeutic effect of HOE/BAY 946 against retroviruses in vivo could be demonstrated in Friend leukaemia virus-infected mice. A clinical pilot study with the compound was started recently in Germany with AIDS patients who did not tolerate or refused to take zidovudine and with asymptomatic virus carriers.
Collapse
Affiliation(s)
- L Biesert
- Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt, Federal Republic of Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|